For those denying the effectiveness of early treatment, this is your legacy:
unnecessary deaths
Based on adoption and early outpatient use of the current best treatment when it was known to be effective from multiple studies at p = 0.01 (ivermectin from Oct 9, 2020, and HCQ from May 19, 2020), and adjusting for the estimated fraction of the world that adopted these treatments. The total number of COVID-19 deaths is
There have been 64 controlled studies of ivermectin for COVID-19, authored by 627 scientists, with 48,637 patients. Meta analysis shows a 67% improvement for early treatment, relative risk 0.33 [0.24-0.47].
There have been 294 controlled studies of HCQ for COVID-19, authored by 4,723 scientists, with 412,766 patients. Meta analysis shows a 64% improvement for early treatment, relative risk 0.36 [0.29-0.46] (HCQ is not effective when used too late).
Many other early treatments are effective, for example vitamin D and bamlanivimab (LY-CoV555). Using multiple treatments, especially with different mechanisms of action, is likely to further reduce deaths.
Chowdhuryhosp., p=0.23Espitia-Hernandezrecov. time, p<0.0001Carvallodeath, p=0.08Mahmuddeath, p=0.25Szente Fonsecahosp., p=0.53Cadegianideath, p=0.50Ahmedsymptoms, p=0.09Chaccoursymptoms, p<0.05Ghauriviral- time, p=0.0008Babalolaviral+, p=0.11Ravikirtideath, p=0.12Bukhariviral+, p<0.0001Mohanno recov., p=0.27Biberhosp., p=0.34Elalfyviral+, p<0.0001López-Medinadeath, p=0.50Royrecov. time, p=0.87Chahlano disch., p=0.004Mouryaviral+, p<0.0001Louedeath, p=0.34Merinohosp., p<0.001Faisalno recov., p=0.005Arefrecov. time, p=0.0001Krolewieckiventilation, p=1.00Vallejosdeath, p=0.70Together Trialdeath, p=0.54Buonfratehosp., p=0.30Mayerdeath, p<0.0001Borodydeath, p=0.03Ivermectin early treatmentShoumansymp. case, p<0.001Carvallocases, p<0.0001Beheracases, p=0.0007Carvallocases, p<0.0001Hellwigcases, p<0.02Bernigauddeath, p=0.08Alamcases, p<0.0001Vallejoscases, p<0.0001Chahlam/s case, p=0.002Beheracases, p<0.001Taniokadeath, p=0.002Seetsymp. case, p=0.01Morgensternhosp., p=0.50Mondalsymp. case, p=0.006Ivermectin prophylaxis% Lower Risk% Increased Risk
Gautretviral+, p=0.001Huangno recov., p=0.02Esperhosp., p=0.02Ashrafdeath, p=0.15Huangviral- time, p<0.0001Guérindeath, p=1.00Chenviral- time, p=0.01Derwanddeath, p=0.12Mitjàhosp., p=0.64Skipperhosp./death, p=0.58Hongviral+, p=0.001Bernabeu-Witteldeath, p=0.03Yudeath, p=0.02Lydeath, p=0.02Ipdeath, p=0.43Herasdeath, p=0.004Kirengarecov. time, p=0.20Sulaimandeath, p=0.01Guisado-Vascodeath, p=0.19Szente Fonsecahosp., p=0.0008Cadegianideath, p=0.21Simovahosp., p=0.01Omranihosp., p=1.00Agustiprogression, p=0.21Suprogression, p=0.006Amaravadino recov., p=0.13Royrecov. time, p=0.96Mokhtarideath, p<0.0001Milliondeath, p=0.0007Sobngwino recov., p=0.44Rodrigueshosp., p=1.00Sawanpanyalertprogression, p=0.37HCQ early treatment studies% Lower Risk% Increased Risk